293 related articles for article (PubMed ID: 32556851)
21. The Role of Statins in Current Guidelines.
Rached F; Santos RD
Curr Atheroscler Rep; 2020 Aug; 22(9):50. PubMed ID: 32770357
[TBL] [Abstract][Full Text] [Related]
22. Lipid-lowering treatment in peripheral artery disease.
Katsiki N; Giannoukas AD; Athyros VG; Mikhailidis DP
Curr Opin Pharmacol; 2018 Apr; 39():19-26. PubMed ID: 29413998
[TBL] [Abstract][Full Text] [Related]
23. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
[TBL] [Abstract][Full Text] [Related]
24. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
25. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Wójcik C
Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
[TBL] [Abstract][Full Text] [Related]
26. Combined lipid-lowering therapy.
Karásek D
Vnitr Lek; 2019; 64(12):1177-1184. PubMed ID: 30704254
[TBL] [Abstract][Full Text] [Related]
27. Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
Collins PD; Sattar N
Curr Cardiol Rep; 2016 Dec; 18(12):133. PubMed ID: 27864787
[TBL] [Abstract][Full Text] [Related]
28. Evolocumab: A Review in Hyperlipidemia.
Keating GM
Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308
[TBL] [Abstract][Full Text] [Related]
29. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
Leiter LA; Zamorano JL; Bujas-Bobanovic M; Louie MJ; Lecorps G; Cannon CP; Handelsman Y
Diabetes Obes Metab; 2017 Jul; 19(7):989-996. PubMed ID: 28206704
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Hyperlipidemia Changes With Level of Kidney Function-Rationale.
Ananthakrishnan S; Kaysen GA
Adv Chronic Kidney Dis; 2016 Jul; 23(4):247-54. PubMed ID: 27324678
[TBL] [Abstract][Full Text] [Related]
31. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
Reklou A; Katsiki N; Karagiannis A; Athyros V
Curr Vasc Pharmacol; 2020; 18(1):38-42. PubMed ID: 30663570
[TBL] [Abstract][Full Text] [Related]
32. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
[TBL] [Abstract][Full Text] [Related]
33. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
34. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
Agrawal S; Zaritsky JJ; Fornoni A; Smoyer WE
Nat Rev Nephrol; 2018 Jan; 14(1):57-70. PubMed ID: 29176657
[TBL] [Abstract][Full Text] [Related]
35. Current status of lipid management in acute coronary syndrome.
Fujisue K; Tsujita K
J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
[TBL] [Abstract][Full Text] [Related]
36. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
37. Practical recommendations for the management of hyperlipidemia.
Fischer S; Schatz U; Julius U
Atheroscler Suppl; 2015 May; 18():194-8. PubMed ID: 25936326
[TBL] [Abstract][Full Text] [Related]
38. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS
Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517
[TBL] [Abstract][Full Text] [Related]
39. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
40. Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients.
Shoji T
Clin Exp Nephrol; 2014 Apr; 18(2):257-60. PubMed ID: 24072417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
